Basilea Pharmaceutica Ltd. Logo
 

Oncology 2014

 
 
 

BAL101553

  • Gupta S. Delineation of current development of antimitotic compounds targeting cytoskeletal protein tubulin and microtubule in the cancer therapy. Curr Chem Biology 2014; (8)3: 165-183.
  • Molife LR, Imseeh G, Capelan M, El-Khouly F, Cresti N, Smith AD, Averion D, Md. Haris N, Stimpson SJ, Gumbleton T, Lane HA, Bachmann F, Schmitt-Hoffmann A, Tzankov A, Hannah AL, Anderson S, Bette U, Calvert AH, Plummer R, Kristeleit RS. Phase I/IIa trial of the novel microtubule inhibitor BAL101553 in advanced solid tumors: Phase I completed. J Clin Oncol. 2014; 32(15).
  • Prota AE, Danel F, Bachmann F, Bargsten K, Buey RM, Pohlmann J, Reinelt S, Lane H, Steinmetz MO. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. J Mol Biol. 2014; 426(8): 1848-1860.
  • AACR, 2014, 831 / BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab. Bachmann F, Burger K, Duran GE, Sikic BI, Lane HA.
  • ASCO, 2014, 2562 / Phase 1/2a trial of the novel microtubule inhibitor BAL101553 in advanced solid tumors: Phase 1 completed. Molife LR, Imseeh G, Capelan M, El-Khouly F, Cresti N, Smith AD, Averion D, Haris NMd, Stimpson SJ, Gumbleton T, Lane HA, Bachmann F, Schmitt-Hoffmann A, Tzankov A, Hannah AL, Anderson S, Bethe U, Calvert AH, Plummer R, Kristeleit RS.
  • EORTC, 2014, 202 / The novel microtubule-destabilizing drug BAL101553 (prodrug of BAL27862) sensitizes a treatment refractory tumor model to ionizing radiation. Broggini-Tenzer A, Bachmann F, Vuong V, Messikommer A, Nytko-Karouzakis K, O'Reilly T, Lane HA, Pruschy MN.
 
Info